Heart Rhythm

Hearts should have normal rhythm to their beats, but when these beats are out of synch, it causes inefficient pumping of blood. Irregular heart arrhythmias occur when the electrical signals that coordinate the heart's beats do not work properly. This can cause beats that are too fast (tachycardia), or too slow (bradycardia). Tachycardias include atrial fibrillation (AFib), supraventricular tachycardia, ventricular fibrillation, and ventricular tachycardia (VT). Bradycardias include sick sinus syndrome and conduction block. Electrophysiology arrhythmia treatments include medications, life style changes, and the EP lab interventions of catheter ablation, and implantable pacemakers or defibrillators.

Johnson & Johnson MedTech launches new 2D ICE catheter
The company says the new device was designed to improve image quality, provide additional maneuverability and simplify ablation workflows for electrophysiologists.
Johnson & Johnson MedTech ordered to pay $147M for antitrust violations
The company told Cardiovascular Business it respectfully disagrees with the jury's decision and is evaluating all possible legal options going forward. The Association of Medical Device Reprocessors, meanwhile, celebrated the news.
Cardiologists are first in world to use new cooling device to terminate AFib during surgery
Patients often develop AFib during cardiac surgery, leading to longer hospital stays, additional healthcare costs and a higher risk of mortality. Cooling the oblique sinus of the patient's heart as soon as AFib starts to develop may represent a new way to stop the problem in its tracks.
World’s first leadless LBBAP procedures linked to ‘promising’ outcomes
Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures.
AI predicts LBBB risk in TAVR patients prior to treatment
The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

OHCA survival varies 1.5-fold from one EMS agency to next

A patient’s odds of surviving out-of-hospital cardiac arrest (OHCA) fluctuate an average of 56 percent from one emergency medical services (EMS) agency to another, researchers reported Sept. 26 in JAMA Cardiology.

TCT.18: Anticipated OAC-ALONE results ‘underpowered, inconclusive’

OAC-ALONE, the first randomized trial to test the efficacy of oral anticoagulation (OAC) alone against combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation and stable coronary artery disease, was unable to establish noninferiority of OACs to dual therapy, according to data presented at the 30th annual TCT conference in San Diego.

OHCA protocol with angiography, therapeutic cooling slashes mortality rates

A strict protocol mandating coronary angiography and therapeutic hypothermia contributed to “startling” improvements in survival rates for out-of-hospital cardiac arrest (OHCA), researchers reported in JACC: Cardiovascular Interventions.

38% of AFib patients feel ‘trapped’ between risks of stroke, anticoagulants

Atrial fibrillation patients are acutely aware of their five-fold increased risk of stroke, new research from StopAfib.org suggests—and 38 percent report feeling “trapped” between their fear of having a stroke and the major bleeding risks associated with anticoagulants.

Study: 89% of athletes survive cardiac arrest with AED use

It’s well-known that automated external defibrillators (AEDs) can be a life-saving tool to treat cardiac arrhythmias, but a new study from the University of Washington underscores just how crucial accessible AEDs can be during competitive sporting events.

Edoxaban more effective than warfarin in Latin American patients with AFib

The direct oral anticoagulant (DOAC) edoxaban is superior to warfarin for mitigating stroke risk in Latin American patients with atrial fibrillation (AFib), according to results of the ENGAGE AF-TIMI trial.

Warfarin vs DOACs: What’s the best indicator for a switch?

Optimal candidates for a switch from vitamin K antagonists like warfarin to direct oral anticoagulants (DOACs) have long been identified by a single statistic—time-in-therapeutic range—but a recent Danish analysis of anticoagulants in atrial fibrillation patients suggests the marker might be less insightful than previously thought.

‘Cardioskin’ T-shirt tracks heart rhythm around the clock

French pharmaceutical company Servier has partnered with Bioserenity to launch a “smart T-shirt” they’re calling the Cardioskin—a wearable innovation that would allow heart patients to monitor their cardiac rhythm throughout the day, the Daily Mail has reported.

Heart Rhythm

Johnson & Johnson MedTech launches new 2D ICE catheter

Johnson & Johnson MedTech ordered to pay $147M for antitrust violations

Cardiologists are first in world to use new cooling device to terminate AFib during surgery

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

AI predicts LBBB risk in TAVR patients prior to treatment